Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
Rhea-AI Summary
Acurx (NASDAQ: ACXP) announced an Australian patent grant for DNA Polymerase IIIC inhibitors, adding to its global intellectual property that already includes three U.S. patents and patents in Israel, Japan and India.
The patent covers compositions of matter tied to the ACX-375C program. Management noted the lead DNA pol IIIC inhibitor is Phase 3-ready for oral C. difficile treatment, while new preclinical compounds are systemically absorbed for potential oral and parenteral use across indications including ABSSSI (MRSA), CABP, HABP/VABP, bacteremia/sepsis, endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax.
Positive
- Australian patent granted for DNA Polymerase IIIC inhibitors
- Patent portfolio now includes 3 U.S. patents plus patents in Israel, Japan, India, and Australia
- Lead DNA pol IIIC inhibitor described as Phase 3-ready for oral C. difficile treatment
- Preclinical compounds reported as systemically absorbed for oral and parenteral use
Negative
- None.
News Market Reaction
On the day this news was published, ACXP declined 8.15%, reflecting a notable negative market reaction. Argus tracked a trough of -13.6% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Robert J. DeLuccia, Executive Chairman of Acurx, stated: "Achieving this patent in
He further stated: "While our lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection, and has validated the bacterial target for DNA pol IIIC inhibitors, our new preclinical compounds are systemically absorbed for potential oral and parenteral use in clinical settings such as acute bacterial skin and skin-structure infections (ABSSSI, including MRSA), Community-acquired bacterial pneumonia (CABP), hospital and/or ventilator-associated bacterial pneumonia (HABP/VABP); bacteremia with or w/o sepsis and/or infectious endocarditis; bone/joint infections, prosthetic joint infections and inhalational anthrax".
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram- positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials as soon as possible. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/australian-patent-office-grants-acurx-patent-for-dna-polymerase-iiic-inhibitors-302579270.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
What did Acurx (ACXP) announce on October 9, 2025?
How many patents does Acurx (ACXP) now hold and where?
What is the development status of Acurx's lead DNA pol IIIC inhibitor (ACXP)?
Which clinical indications could Acurx's new compounds target for ACXP?
Does the Australian patent cover compositions of matter for ACX-375C (ACXP)?
